Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07406932 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Study on the Efficacy and Safety of JAK Inhibitors Versus Calcineurin Inhibitors as Initial Therapy for Interstitial Lung Disease Associated With Antisynthetase Syndrome

Name: A Study on the Efficacy and Safety of JAK Inhibitors Versus Calcineurin Inhibitors as Initial Therapy for Interstitial Lung Disease Associated With Antisynthetase Syndrome — clinical trial record (NCT07406932)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Study acronym: JAKCNIASSILD

StatusRecruiting

PhaseNot applicable

SponsorChina-Japan Friendship Hospital

Started2026-05-18

View on ClinicalTrials.gov ↗

Amendment history

2026-05-31

Study Status, Eligibility, Contacts/Locations v1

Recruitment opened

Start date2026-02-01→2026-05-18

Study sites0→1

2026-02-06

Original filing

China-Japan Friendship Hospital

97 trials monitored

See 2 trials at risk

This study is a prospective investigation comparing the efficacy and safety of Janus kinase inhibitors versus calcineurin inhibitors as initial therapy for interstitial lung disease associated with antisynthetase syndrome. The goal is to determine which treatment is more effective at improving lung function and preventing disease progression, while comparing their safety profiles. The findings will help provide clearer treatment guidance for doctors and patients.

Trial Details

NCT Number	NCT07406932
Lead Sponsor	China-Japan Friendship Hospital
Conditions	Antisynthetase Syndrome, Interstitial Lung Disease (ILD)
Enrollment	80 participants
Start Date	2026-05-18
Primary Completion	2027-07-01 (estimated)
Study Completion	2027-07-01 (estimated)
Updated on ClinicalTrials.gov	2026-06-03